Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer
Excerpt:...PD-L1 expression 1% 6....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
Excerpt:...- High tumor tissue PD-L1 expression...
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
Excerpt:...The specimen is considered to have PD-L1 expression if TPS ≥ 1% and high PD-L1 expression if TPS ≥ 50%....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Excerpt:...Independent Review Facility (IRF)-assessed Progression Free Survival (PFS) in the PD-L1-positive Analysis Set (PPAS)`IRF-assessed PFS in the Full Analysis Set (FAS)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
Excerpt:...Overall Survival (Phase 2)`PFS as Determined by an Independent Review Facility (IRF) (Phase 3)`Investigator-assessed PFS in Participants With PD-L1 Expression at TC ≥50% and TC ≥1% Cut-off, as Determined by Central Testing With Ventana PD-L1 (SP263) Assay (Phase 3)`OS in Participants With PD-L1 Expression at TC ≥50% and TC ≥1% Cut-off, as Determined by Central Testing With Ventana PD-L1 (SP263) Assay (Phase 3)`Investigator-Assessed PFS at 6 Months and 12 Months (Phase 3)`OS Rate at 12 Months and 24 Months (Phase 3)`Investigator-Assessed Confirmed ORR (Phase 3)`Investigator-Assessed Duration of Response (DOR) (Phase 2 and Phase 3)`Time to Confirmed Deterioration (TTCD) in Participant-Reported Physical Functioning and Global Health Status (GHS)/Quality of Life (QoL) as Measured by European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (Phase 2 and Phase 3)`TTCD in Participant-Reported Lung Cancer Symptoms for Cough, Dyspnea, and Chest Pain, as Measured by EORTC QLQ-LC13 (Phase 2 and Phase 3)`Percentage of Participants With Adverse Events (AEs) (Phase 2 and Phase 3)`Participants' Response to Side Effects of Treatment as Assessed by EORTC IL46 (Phase 2 and Phase 3)`Serum Concentration of Tiragolumab (Phase 2 and Phase 3)`Serum Concentration of Atezolizumab (Phase 2 and Phase 3)`Percentage of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab (Phase 2 and Phase 3)`Percentage of Participants With ADAs to Atezolizumab (Phase 2 and Phase 3)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Excerpt:...- Tumor PD-L1 expression...
Less C2 evidence
Evidence Level:Sensitive: C3 – Early Trials
Title:
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Excerpt:Tiragolumab plus atezolizumab showed a clinically meaningful improvement in objective response rate and progression-free survival compared with placebo plus atezolizumab in patients with chemotherapy-naive, PD-L1-positive, recurrent or metastatic NSCLC.
DOI:https://doi.org/10.1016/S1470-2045(22)00226-1
Evidence Level:Sensitive: C3 – Early Trials
Title:
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
Excerpt:This prospective, randomized, double-blind, placebo-controlled trial enrolled patients (pts) with chemotherapy-naïve PD-L1+ (TPS ≥ 1% by 22C3 IHC pharmDx Dako assay) locally advanced or metastatic NSCLC...At primary analysis (30 Jun 2019), TA improved ORR and median PFS (mPFS) compared to PA, with median follow-up of 5.9 mo...With an additional six months of follow-up since the primary analysis (2 Dec 2019, median follow-up of 10.9 mo), improvement in ORR and mPFS was maintained in ITT for TA (37.3% [25.0, 49.6] and 5.6 mo [4.2, 10.4]) vs PA (20.6% [10.2, 30.9] and 3.9 mo [2.7, 4.5]).
DOI:10.1200/JCO.2020.38.15_suppl.9503
